140 related articles for article (PubMed ID: 1814746)
1. Histopathological change of corpora cavernosa after long-term intracavernous injection.
Hwang TI; Yang CR; Ho WL; Chu HW
Eur Urol; 1991; 20(4):301-6. PubMed ID: 1814746
[TBL] [Abstract][Full Text] [Related]
2. Chronic papaverine treatment: the effect of repeated injections on the simian erectile response and penile tissue.
Abozeid M; Juenemann KP; Luo JA; Lue TF; Yen TS; Tanagho EA
J Urol; 1987 Nov; 138(5):1263-6. PubMed ID: 3669186
[TBL] [Abstract][Full Text] [Related]
3. Local and systemic effects of chronic intracavernous injection of papaverine, prostaglandin E1, and saline in primates.
Aboseif SR; Breza J; Bosch RJ; Benard F; Stief CG; Stackl W; Lue TF; Tanagho EA
J Urol; 1989 Aug; 142(2 Pt 1):403-8. PubMed ID: 2746759
[TBL] [Abstract][Full Text] [Related]
4. [Prostaglandin E1 in erectile dysfunction].
Porst H
Urologe A; 1989 Mar; 28(2):94-8. PubMed ID: 2655258
[TBL] [Abstract][Full Text] [Related]
5. A comparative study with intracavernous injection of prostaglandin E1 versus papaverine for the diagnostic assessment of erectile impotence.
Wang CJ; Wu CC; Huang CH; Chiang CP
Gaoxiong Yi Xue Ke Xue Za Zhi; 1992 Nov; 8(11):585-90. PubMed ID: 1296038
[TBL] [Abstract][Full Text] [Related]
6. Short-term histopathologic effects of different intracavernosal agents on corpus cavernosum and antifibrotic activity of intracavernosal verapamil: an experimental study.
Sahin M; Başar MM; Bozdoğan O; Atan A
Urology; 2001 Sep; 58(3):487-92. PubMed ID: 11549511
[TBL] [Abstract][Full Text] [Related]
7. Comparison of a mixture of papaverine, phentolamine and prostaglandin E1 with other intracavernous injections.
Meinhardt W; Lycklama à Nijeholt AA; Kropman RF; Vermeij P; Zwartendijk J
Eur Urol; 1994; 26(4):319-21. PubMed ID: 7713130
[TBL] [Abstract][Full Text] [Related]
8. Intracavernous drug delivery system: an alternative to intracavernous injection in the treatment of impotence?
Stief CG; Wetterauer U; Kulvelis F; Popken G; Staubesand J; Sommerkamp H
Urol Int; 1990; 45(6):321-5. PubMed ID: 2288047
[TBL] [Abstract][Full Text] [Related]
9. Intracavernous self-injection therapy for the treatment of erectile dysfunction.
Chiang HS; Wen TC; Wu CC; Chiang WH
J Formos Med Assoc; 1992 Sep; 91(9):898-901. PubMed ID: 1363391
[TBL] [Abstract][Full Text] [Related]
10. [Evaluation of 452 patients with erectile dysfunction treated by combinations of vasoactive agents by penile injection].
Segenreich E; Israilov S; Shmueli J; Simon D; Baniel J; Livne P
Harefuah; 1998 May; 134(9):673-8, 750. PubMed ID: 10909609
[TBL] [Abstract][Full Text] [Related]
11. Comparison of effects following the intracorporeal injection of papaverine and prostaglandin E1.
Chen JK; Hwang TI; Yang CR
Br J Urol; 1992 Apr; 69(4):404-7. PubMed ID: 1581812
[TBL] [Abstract][Full Text] [Related]
12. Comparison of penile vascular effect induced by intracavernous injection of papaverine and prostaglandin E1.
Hwang TI; Lue TF; Yang CR; Chang CL; Chang CH; Wu HC
Taiwan Yi Xue Hui Za Zhi; 1989 Oct; 88(10):1038-41. PubMed ID: 2634727
[TBL] [Abstract][Full Text] [Related]
13. The rabbit as an intracavernous injection study model.
Lin YM; Lin JS
Urol Res; 1996; 24(1):27-32. PubMed ID: 8966838
[TBL] [Abstract][Full Text] [Related]
14. [Intracavernous pharmacotherapy for treatment and evaluation of impotence].
Vardi Y; Lidgi S; Moskovitz B; Levin RD
Harefuah; 1991 Oct; 121(7-8):223-5. PubMed ID: 1783307
[TBL] [Abstract][Full Text] [Related]
15. [Intracavernous injection of vasoactive drugs for treating erectile impotence].
Yasumoto R; Asakawa M; Kawashima H; Yoshimura R; Maekawa T; Kashiwara N; Tanaka H; Nishio S
Hinyokika Kiyo; 1988 Feb; 34(2):301-4. PubMed ID: 2454019
[TBL] [Abstract][Full Text] [Related]
16. [Long-term results of the treatment with intracavernous injection of vasoactive drugs].
Rodríguez Vela L; Gonzalvo Ibarra A; Gil Martínez P; Benejan Gual J; Cuesta Presedo JM; Ríoja Sanz LA
Arch Esp Urol; 1996 Apr; 49(3):257-69. PubMed ID: 8702347
[TBL] [Abstract][Full Text] [Related]
17. Nocturnal penile tumescence activity unchanged after long-term intracavernous injection therapy.
Maniam P; Seftel AD; Corty EW; Rutchik SD; Hampel N; Althof SE
J Urol; 2001 Mar; 165(3):830-2; discussion 832-3. PubMed ID: 11176480
[TBL] [Abstract][Full Text] [Related]
18. Quantification of prostaglandin E1 receptors in cavernous tissue of men, monkeys and dogs.
Aboseif S; Riemer RK; Stackl W; Lue T; Tanagho E
Urol Int; 1993; 50(3):148-52. PubMed ID: 8465481
[TBL] [Abstract][Full Text] [Related]
19. [The use of PGE1 in the treatment of erectile deficiency].
Arena F; Peracchia G; Di Stefano C; Cortellini P
Acta Biomed Ateneo Parmense; 1996; 67(1-2):49-53. PubMed ID: 10021734
[TBL] [Abstract][Full Text] [Related]
20. Intracavernous self-injection of prostaglandin E1 in the treatment of erectile dysfunction.
Kunelius P; Lukkarinen O
Int J Impot Res; 1999 Feb; 11(1):21-4. PubMed ID: 10098949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
